In a Bloomberg survey based on the recommendations of 24 brokerage companies, Edwards Lifesciences (EW) was given “buy” ratings by ~71% of analysts. About 25% issued “hold” recommendations, and only one issued a “sell” recommendation on the stock.
Receive e-mail alerts for new research on BSX:
Interested in BSX?
Don’t miss the next report.
The table above lists the 17 brokerage companies that have provided target prices for Edwards Lifesciences for the next 12 months. The consensus 12-month target price is $121.4, which amounts to a ~28.8% return potential, compared to Edwards Lifesciences’ price of $94.2 on October 26, 2016.
According to the latest analysts’ ratings update after EW’s earnings release, Northland Securities and Evercore gave the company a one-year target price of $105, the lowest target price among analysts, implying an ~11.4% return over the next 12 months.
Among the large investment banks, JPMorgan Chase gave Edwards Lifesciences a one-year target price of $135, implying a ~48.5% return potential over the next 12 months.
Morgan Stanley and Canaccord Genuity gave the stock its highest one-year target price of $140, implying a return of ~48.5%.
Peers Medtronic (MDT), Boston Scientific (BSX), and St. Jude Medical (STJ) have average broker target prices of $94.7, $27.9, and $81.5, respectively. These figures imply returns of 16.8%, 26.3%, and 3.6%, respectively, over the next 12 months.
Investors can gain diversified exposure to Edwards Lifesciences by investing in the Vanguard Growth ETF (VUG). VUG has 0.23% of its total holdings in Edwards Lifesciences.